A worldwide overview for hexavalent vaccines and a glimpse into Turkiye’s perspective

References

• Skibinski D, Baudner B, Singh M, O´SQª Hagan D. Combination vaccines. J Glob Infect Dis. 2011;3(1):63–11. doi:10.4103/0974-777X.77298.
   PubMedGoogle Scholar
• Maman K, Zöllner Y, Greco D, Duru G, Sendyona S, Remy V. The value of childhood combination vaccines: from beliefs to evidence. Hum Vaccin Immunother. 2015;11(9):2132–41. doi:10.1080/21645515.2015.1044180.
   PubMed Web of Science ®Google Scholar
• WHO. Implementing the immunisation agenda 2030: a framework for action through coordinated planning, monitoring & evaluation, ownership & accountability, and communications & advocacy; 2021. https://www.immunizationagenda2030.org/framework-for-action
   Google Scholar
• Ellis RW. Development of combination vaccines. Vaccine. 1999;17(13–14):1635–42. doi:10.1016/S0264-410X(98)00424-1.
   PubMed Web of Science ®Google Scholar
• Parkman PD. Combined and simultaneously administered vaccines. A brief history. Ann N Y Acad Sci. 1995;754(1):1–9. doi:10.1111/j.1749-6632.1995.tb44431.x.
   PubMedGoogle Scholar
• Keja K, Chan C, Hayden G, Henderson RH. Expanded programme on immunization. World Health Stat Quarterly. 1988;41:59–63.
   PubMedGoogle Scholar
• De Coster I, Fournie X, Faure C, Ziani E, Nicolas L, Soubeyrand B, Van Damme P. Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalent vaccines. A time and motion study. Vaccine. 2015;33(32):3976–82. doi:10.1016/j.vaccine.2015.06.030.
   PubMed Web of Science ®Google Scholar
• King GE, Hadler SC. Simultaneous administration of childhood vaccines: an important public health policy that is safe and efficacious. Pediatr Infect Dis J. 1994;13(5):394–407. doi:10.1097/00006454-199405000-00012.
   PubMed Web of Science ®Google Scholar
• Dodd D. Benefits of combination vaccines: effective vaccination on a simplified schedule. Am J Manag Care. 2003;9:S6–12.
   PubMed Web of Science ®Google Scholar
• Madlon-Kay DJ, Harper PG. Too many shots? Parent, nurse, and physician attitudes toward multiple simultaneous childhood vaccinations. Arch Fam Med. 1994;3(7):610–3. doi:10.1001/archfami.3.7.610.
   PubMedGoogle Scholar
• Melman ST, Nguyen TT, Ehrlich E, Schorr M, Anbar RD. Parental compliance with multiple immunization injections. Arch Pediatr Adolesc Med. 1999;153(12):1289–91. doi:10.1001/archpedi.153.12.1289.
   PubMed Web of Science ®Google Scholar
• Scheifele DW, Halperin SA, Ferguson AC. Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens. Vaccine. 2001;19(32):4720–6. doi:10.1016/S0264-410X(01)00230-4.
   PubMed Web of Science ®Google Scholar
• Beyazova U, Yüksel N, Aksakal FN, Camurdan AD. Comparison of the reactogenicity of three different immunization schedules including diphtheria, tetanus, pertussis, haemophilus influenza b and polio vaccine in Turkey. Trans R Soc Trop Med Hyg. 2013;107(7):438–43. doi:10.1093/trstmh/trt039.
   PubMed Web of Science ®Google Scholar
• Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25(6):507–12. doi:10.1097/01.inf.0000222413.47344.23.
   PubMed Web of Science ®Google Scholar
• Kaaijk P, Kleijne DE, Knol MJ, Harmsen IA, Ophorst OJ, Rots NY. Parents’ attitude toward multiple vaccinations at a single visit with alternative delivery methods. Hum Vaccin Immunother. 2014;10(8):2483–9. doi:10.4161/hv.29361.
   PubMed Web of Science ®Google Scholar
• Wilburn SQ, Eijkemans G. Preventing needlestick injuries among healthcare workers: a WHO-ICN collaboration. Int J Occup Environ Health. 2004;10(4):451–6. doi:10.1179/oeh.2004.10.4.451.
   PubMed Web of Science ®Google Scholar
• Icardi G, Orsi A, Vitali Rosati G, Tognetto A, Checcucci Lisi G, Parisi S. Preferences of healthcare professionals regarding hexavalent pediatric vaccines in Italy: a survey of attitudes and expectations. J Prev Med Hyg. 2020;61(3):E424–e44. doi:10.15167/2421-4248/jpmh2020.61.3.1535.
   PubMedGoogle Scholar
• Koslap-Petraco MB, Parsons T. Communicating the benefits of combination vaccines to parents and health care providers. J Pediatr Health Care. 2003;17(2):53–7. doi:10.1067/mph.2003.42.
   PubMedGoogle Scholar
• Decker MD. Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatr Infect Dis J. 2001;20(11 Suppl):S10–8. doi:10.1097/00006454-200111001-00002.
   PubMed Web of Science ®Google Scholar
• Research USDoHaHSFaDACfBEa. Guidance for industry for the evaluation of combination vaccines for preventable diseases: production, testing and clinical studies. 1997.
   Google Scholar
• Obando-Pacheco P, Rivero-Calle I, Gómez-Rial J, Rodríguez-Tenreiro Sánchez C, Martinón-Torres F. New perspectives for hexavalent vaccines. Vaccine. 2018;36(36):5485–94. doi:10.1016/j.vaccine.2017.06.063.
   PubMed Web of Science ®Google Scholar
• Le CT. Combination vaccines: choices or chaos? A practitioner’s perspective. Clin Infect Dis. 2001;33(Supplement_4):367–71. doi:10.1086/322575.
   Google Scholar
• Moro PL, Arana J, Marquez PL, Ng C, Barash F, Hibbs BF, Cano M. Is there any harm in administering extra-doses of vaccine to a person? Excess doses of vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2007–2017. Vaccine. 2019;37(28):3730–4. doi:10.1016/j.vaccine.2019.04.088.
   PubMed Web of Science ®Google Scholar
• Esposito S, Tagliabue C, Bosis S, Ierardi V, Gambino M, Principi N. Hexavalent vaccines for immunization in paediatric age. Clin Microbiol Infec. 2014;20(s5):76–85. doi:10.1111/1469-0691.12444.
   PubMedGoogle Scholar
• Aquino AGB, Brito MG, Doniz CEA, Herrera JFG, Macias M, Zambrano B, Plennevaux E, Santos-Lima E. A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children. Vaccine. 2012;30(45):6492–500. doi:10.1016/j.vaccine.2012.07.040.
   PubMed Web of Science ®Google Scholar
• Kosalaraksa P, Thisyakorn U, Benjaponpitak S, Chokephaibulkit K, Santos-Lima E. Immunogenicity and safety study of a new DTaP–IPV–Hep B–PRP-T combined vaccine compared to a licensed DTaP–IPV–Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants. Int J Infect Dis. 2011;15(4):249–56. doi:10.1016/j.ijid.2010.12.004.
   PubMed Web of Science ®Google Scholar
• López P, Arguedas Mohs A, Abdelnour Vásquez A, Consuelo-Miranda M, Feroldi E, Noriega F, Jordanov E, B′chir S, Zambrano B. A randomized controlled study of a fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primary and booster vaccinations of healthy infants and toddlers in Latin America. Pediatr Infect Dis J. 2017;36(11):272–82. doi:10.1097/INF.0000000000001682.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Silfverdal S-A, Jordanov E, Randomized FEA. Controlled study of DTaP-IPV-HB-PRP-T, a fully liquid hexavalent vaccine, administered in a 3-, 5- and 11- to 12-month schedule. Pediatr Infect Dis J. 2017;36(1):87–93. doi:10.1097/INF.0000000000001358.
   PubMed Web of Science ®Google Scholar
• Silfverdal S-A, Icardi G, Vesikari T, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, Thomas S, et al. A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11–12 months. Vaccine. 2016;34(33):3810–6. doi:10.1016/j.vaccine.2016.05.054.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Becker T, Vertruyen AF, Poschet K, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, et al. A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at two, three, four and twelve months. Pediatr Infect Dis J. 2017;36(2):209–15. doi:10.1097/INF.0000000000001406.
   PubMed Web of Science ®Google Scholar
• Syed YY. DTaP-IPV-HepB-Hib vaccine (Hexyon®): an updated review of its use in primary and booster vaccination. Pediatr Drugs. 2019;21(5):397–408. doi:10.1007/s40272-019-00353-7.
   PubMed Web of Science ®Google Scholar
• Tichmann-Schumann I, Soemantri P, Behre U, Disselhoff J, Mahler H, Maechler G, Sänger R, Jacquet J-M, Schuerman L. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2005;24(1):70–7. doi:10.1097/01.inf.0000148923.46453.48.
   PubMed Web of Science ®Google Scholar
• Schmitt HJ, Knuf M, Ortiz E, Sänger R, Uwamwezi MC, Kaufhold A. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and haemophilus influenzae type b vaccines given as either separate or mixed injections. J Pediatr. 2000;137(3):304–12. doi:10.1067/mpd.2000.107796.
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Blatter MM, Reisinger KS, Harrison CJ, Johnson CE, Steinhoff MC, Senders SD, Rothstein EP, Willems P, Howe BJ, et al. Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-haemophilus influenzae type b combination vaccination. Pediatr Infect Dis J. 2002;21(9):854–9. doi:10.1097/00006454-200209000-00014.
   PubMed Web of Science ®Google Scholar
• Arístegui J, Dal-Ré R, Díez-Delgado J, Marés J, Casanovas JM, García-Corbeira P, De Frutos E, Van Esso D, Verdaguer J, De la Flor J, et al. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Vaccine. 2003;21(25–26):3593–600. doi:10.1016/s0264-410x(03)00420-1.
   PubMed Web of Science ®Google Scholar
• Nolan T, Altmann A, Skeljo M, Streeton C, Schuerman L. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine. Vaccine. 2004;23(1):14–20. doi:10.1016/j.vaccine.2004.06.017.
   PubMed Web of Science ®Google Scholar
• Zepp F, Knuf M, Heininger U, Jahn K, Collard A, Habermehl P, Schuerman L, Sänger R. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine. 2004;22(17–18):2226–33. doi:10.1016/j.vaccine.2003.11.044.
   PubMed Web of Science ®Google Scholar
• Omeñaca F, Garcia-Sicilia J, García-Corbeira P, Boceta R, Romero A, Lopez G, Dal-Ré R. Response of preterm newborns to immunization with a hexavalent diphtheria–tetanus–acellular pertussis–hepatitis B virus–inactivated polio and haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. Pediatrics. 2005;116(6):1292–8. doi:10.1542/peds.2004-2336.
   PubMed Web of Science ®Google Scholar
• Knuf M, Habermehl P, Cimino C, Petersen G, Schmitt HJ. Immunogenicity, reactogenicity and safety of a 7-valent Pneumococcal Conjugate Vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine. 2006;24(22):4727–36. doi:10.1016/j.vaccine.2006.03.032.
   PubMed Web of Science ®Google Scholar
• Tichmann I, Grunert D, Habash S, Preidel H, Schult R, Pfletschinger U, Gildberg PK, Meurice F, Sänger R. Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and haemophilus influenzae type B vaccines and evaluation of booster vaccination. Hum Vaccin. 2006;2(6):249–54. doi:10.4161/hv.2.6.3432.
   PubMed Web of Science ®Google Scholar
• Heininger U, Sänger R, Jacquet JM, Schuerman L. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Vaccine. 2007;25(6):1055–63. doi:10.1016/j.vaccine.2006.09.060.
   PubMed Web of Science ®Google Scholar
• Omeñaca F, Garcia-Sicilia J, García-Corbeira P, Boceta R, Torres V. Antipolyribosyl ribitol phosphate response of premature infants to primary and booster vaccination with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus/Haemophilus influenzae type b vaccine. Pediatrics. 2007;119(1):e179–85. doi:10.1542/peds.2005-2907.
   PubMed Web of Science ®Google Scholar
• Van Der Meeren O, Bleckmann G, Crasta PD. Immune memory to hepatitis B persists in children aged 7-8 years, who were vaccinated in infancy with 4 doses of hexavalent DTPa-HBV-IPV/Hib (Infanrix™ hexa) vaccine. Hum Vaccin Immunother. 2014;10(6):1682–7. doi:10.4161/hv.28480.
   PubMed Web of Science ®Google Scholar
• Zepp F, Schmitt HJ, Cleerbout J, Verstraeten T, Schuerman L, Jacquet JM. Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines. 2009;8(6):663–78. doi:10.1586/erv.09.32.
   PubMed Web of Science ®Google Scholar
• Behre U, Van Der Meeren O, Crasta P, Hanssens L, Mesaros N. Lasting immune memory against hepatitis B in 12–13-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy. Hum Vaccines Immunother. 2016;12(11):2916–20. doi:10.1080/21645515.2016.1202388.
   PubMed Web of Science ®Google Scholar
• Baldo V, Bonanni P, Castro M, Gabutti G, Franco E, Marchetti F, Prato R, Vitale F. Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-haemophilus influenzae type b vaccine; Infanrix™ hexa. Hum Vaccines Immunother. 2014;10(1):129–37. doi:10.4161/hv.26269.
   PubMed Web of Science ®Google Scholar
• Dolhain J, Janssens W, Mesaros N, Hanssens L, Fierens F. Hexavalent vaccines: increasing options for policy-makers and providers. A review of the data supporting interchangeability (substitution with vaccines containing fewer antigens) and mixed schedules from the same manufacturer. Expert Rev Vaccines. 2018;17(6):513–24. doi:10.1080/14760584.2018.1419070.
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Zambrano B, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. Pediatr Infect Dis J. 2011;30(6):88–96. doi:10.1097/INF.0b013e318212eb80.
   PubMed Web of Science ®Google Scholar
• Lanata C, Zambrano B, Ecker L, Amemiya I, Gil A, Santos-Lima E. Immunogenicity and safety of a fully liquid DTaP-IPV-Hep B-PRP-T vaccine at 2-4-6 months of age in Peru. J Vaccines Vaccin. 2012;3(1):1000128. doi:10.4172/2157-7560.1000128.
   Google Scholar
• Martinón-Torres F, Diez-Domingo J, Feroldi E, Jordanov E, B’Chir S, Da Costa X. Evaluation of a hexavalent-pentavalent-hexavalent infant primary vaccination series followed by a pentavalent booster vaccine in healthy infants and toddlers. Pediatr Infect Dis J. 2019;38(3):317–22. doi:10.1097/INF.0000000000002231.
   PubMed Web of Science ®Google Scholar
• Kim YK, Vidor E, Kim HM, Shin SM, Lee KY, Cha SH, Ma SH, Kim DH, Lee J, Park SE, et al. Immunogenicity and safety of a fully liquid DTaP-IPV-HB-PRP∼T hexavalent vaccine compared with the standard of care in infants in the Republic of Korea. Vaccine. 2017;35(32):4022–8. doi:10.1016/j.vaccine.2017.05.062.
   PubMed Web of Science ®Google Scholar
• Ceyhan M, Yıldırım İ, Tezer H, Devrim İ, Feroldi E. A fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Turkish infants and toddlers. Turk J Med Sci. 2017;47(4):1247–56. doi:10.3906/sag-1609-62.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Borrow R, Da Costa X, Richard P, Eymin C, Boisnard F, Lockhart S. Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants. Vaccine. 2017;35(3):452–8. doi:10.1016/j.vaccine.2016.11.053.
   PubMed Web of Science ®Google Scholar
• Prymula R, Kieninger D, Feroldi E, Jordanov E, B’Chir S, DaCosta X. Immunogenicity and safety of primary and booster vaccinations of a fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine in healthy infants and toddlers in Germany and the Czech Republic. Pediatr Infect Dis J. 2018;37(8):823–30. doi:10.1097/INF.0000000000002109.
   PubMed Web of Science ®Google Scholar
• Ceyhan M, Yildirim I, Tezer H, Devrim I, Feroldi E. A fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primaryand booster vaccination of healthy Turkish infants and toddlers. Turk J Med Sci. 2017;47(4):1247–56. doi:10.3906/sag-1609-62.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Borrow R, Da Costa X, Thomas S, Eymin C, Boisnard F, Lockhart S. Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers. Vaccine. 2018;36(52):8019–27. doi:10.1016/j.vaccine.2018.10.100.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Koen A, Cutland C, Groome M, Santos-Lima E. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15–18 months of age in healthy South African infants. Pediatr Infect Dis J. 2013;32(8):889–97. doi:10.1097/INF.0b013e318292f7b1.
   PubMed Web of Science ®Google Scholar
• Maertens K, Orije MRP, Huoi C, Boisnard F, Lyabis O. Immunogenicity of a liquid hexavalent DTaP-IPV-HB-PRP∼T vaccine after primary and booster vaccination of term and preterm infants born to women vaccinated with Tdap during pregnancy. Vaccine. 2023;41(3):795–804. doi:10.1016/j.vaccine.2022.12.021.
   PubMed Web of Science ®Google Scholar
• Marshall GS, Adams GL, Leonardi ML, Petrecz M, Flores SA, Ngai AL, Xu J, Liu G, Stek JE, Foglia G, et al. Immunogenicity, safety, and tolerability of a hexavalent vaccine in infants. Pediatrics. 2015;136(2):323–32. doi:10.1542/peds.2014-4102.
   PubMed Web of Science ®Google Scholar
• Block SL, Klein NP, Sarpong K, Russell S, Fling J, Petrecz M, Flores S, Xu J, Liu G, Stek JE, et al. Lot-to-lot consistency, safety, tolerability and immunogenicity of an investigational hexavalent vaccine in US infants. Pediatr Infect Dis J. 2017;36(2):202–8. doi:10.1097/INF.0000000000001405.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Xu J, Johnson DR, Hall J, Marček T, Goveia MG, Lee AWT. Hepatitis B and pertussis antibodies in 4- to 5-year-old children previously vaccinated with different hexavalent vaccines. Hum Vaccines Immunother. 2020;16(4):867–74. doi:10.1080/21645515.2019.1673119.
   PubMed Web of Science ®Google Scholar
• Knuf M, Haas H, Garcia-Corbeira P, Turriani E, Mukherjee P, Janssens W, Berlaimont V. Hexavalent vaccines: what can we learn from head-to-head studies? Vaccine. 2021;39(41):6025–36. doi:10.1016/j.vaccine.2021.08.086.
   PubMed Web of Science ®Google Scholar
• Vaxelis EMA summary of product characteristics [ press release]. https://www.ema.europa.eu/en/medicines/human/EPAR/vaxelis.
   Google Scholar
• Zepp F, Schmitt H-J, Cleerbout J, Verstraeten T, Schuerman L, Jacquet J-M. Review of 8 years of experience with Infanrix hexa™ (DTPa–HBV–IPV/Hib hexavalent vaccine). Expert Rev Vaccines. 2009;8(6):663–78. doi:10.1586/erv.09.32.
   PubMed Web of Science ®Google Scholar
• Nunes MC, Madhi SA. Review of a new fully liquid, hexavalent vaccine: Hexaxim. Expert Opin Biol Ther. 2013;13(4):575–93. doi:10.1517/14712598.2013.774368.
   PubMed Web of Science ®Google Scholar
• Bulik NB. Hexavalent vaccine in europe: safety data from the randomized clinical trials. FARMACIA. 2018;66(5):747–57. doi:10.31925/farmacia.2018.5.2.
   Web of Science ®Google Scholar
• Orsi A, Azzari C, Bozzola E, Chiamenti G, Chirico G, Esposito S, Francia F, Lopalco P, Prato R, Russo R, et al. Hexavalent vaccines: characteristics of available products and practical considerations from a panel of Italian experts. J Prev Med Hyg. 2018;59(2):107–19. doi:10.1016/j.vaccine.2017.06.063.
   PubMedGoogle Scholar
• Vidor E, Soubeyrand B. Manufacturing DTaP-based combination vaccines: industrial challenges around essential public health tools. Expert Rev Vaccines. 2016;15(12):1575–82. doi:10.1080/14760584.2016.1205492.
   PubMed Web of Science ®Google Scholar
• Health IMo. National vaccination plan 2017–2019; 2017. https://www.salute.gov.it/imgs/C_17_pubblicazioni_2571_allegato.pdf.
   Google Scholar
• Casula M, Toth F. The 2017 Italian reform on mandatory childhood vaccinations: analysis of the policy process and early implementation. Health Policy. 2021;125(1):7–11. doi:10.1016/j.healthpol.2020.11.004.
   PubMed Web of Science ®Google Scholar
• Kalies H, Grote V, Siedler A, Gröndahl B, Schmitt H-J, von Kries R. Effectiveness of hexavalent vaccines against invasive haemophilus influenzae type b disease: Germany’s experience after 5 years of licensure. Vaccine. 2008;26(20):2545–52. doi:10.1016/j.vaccine.2008.03.001.
   PubMed Web of Science ®Google Scholar
• Lang S, Loving S, McCarthy ND, Ramsay ME, Salisbury D, Pollard AJ. Two centuries of immunisation in the UK (part II). Arch Dis Child. 2020;105(3):216–22. doi:10.1136/archdischild-2019-317707.
   PubMed Web of Science ®Google Scholar
• Recommended child and adolescent immunization schedule for ages 18 years or younger. United States, 2021 [press release]. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf.
   Google Scholar
• Wodi AP, Murthy N, Bernstein H, McNally V, Cineas S, Ault K. Advisory committee on immunization practices recommended immunization schedule for children and adolescents aged 18 years or younger – United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(7):234–7. doi:10.15585/mmwr.mm7107a2.
   PubMed Web of Science ®Google Scholar
• Bayliss J, Nissen M, Prakash D, Richmond P, Oh KB, Nolan T. Control of vaccine preventable diseases in Australian infants: reviewing a decade of experience with DTPa-HBV-IPV/Hib vaccine. Hum Vaccin Immunother. 2021;17(1):176–90. doi:10.1080/21645515.2020.1764826.
   PubMed Web of Science ®Google Scholar
• Sánchez-González G, Luna-Casas G, MascareñMascareñAs C, Macina D, Vargas-Zambrano JC. Pertussis in Mexico from 2000 to 2019: a real-world study of incidence, vaccination coverage, and vaccine effectiveness. Vaccine. 2023;41(41):6105–11. doi:10.1016/j.vaccine.2023.08.046.
   PubMed Web of Science ®Google Scholar
• Kurugol Z. Pertussis epidemiology in Turkey: are booster doses necessary?/Turkiye’de bogmaca epidemiyolojisi pekistirme asi dozlari gerekli mi? J Pediatr Infect. 2009;3:14–18.
   Google Scholar
• T.C. Ministry of health general directorate of health information systems. Health Statistics Yearbook 2017 Newsletter; 2018. 2019.
   Google Scholar
• Türkiye Sağlıkta Dönüşüm Programı Değerlendirme Raporu. [press release]. https://ekutuphane.saglik.gov.tr/Yayin/453.
   Google Scholar
• Turkey’s national immunization program. https://covid19asi.saglik.gov.tr/EN-80229/turkeys-national-immunization-program–.html.
   Google Scholar
• World Health Organization. 2020. https://www.who.int/news-room/detail/22-05-2020-at-least-80-million-children-under-one-at-risk-of-diseases-such-as-diphtheria-measles-and-polio-as-covid-19-disrupts-routine-vaccination-efforts-warn-gavi-who-and-unicef.
   Google Scholar
• Kara A, İlbay S, Topaç O, Arabulan EA, Tezer H, Tavukçu N, Şimşek Ç. Alteration in vaccination rates and an evaluation of physicians’ perceptions of the possible impact of the SARS-CoV-2 pandemic on childhood vaccinations in Ankara, Turkey. Hum Vaccin Immunother. 2021;17(10):3457–62. doi:10.1080/21645515.2021.1923345.
   PubMed Web of Science ®Google Scholar
• Kara SS, Polat M, Yayla BC, Demirdag TB, Tapisiz A, Tezer H, Camurdan AD. Parental vaccine knowledge and behaviours: a survey of Turkish families. East Mediterr Health J. 2018;24(5):451–8. doi:10.26719/2018.24.5.451.
   PubMed Web of Science ®Google Scholar
• Öztaş D, Kurt B, Akbaba M, Akyol M, Mollahaliloğlu S, Topaç O. Vaccination rates for Syrian population under temporary protection in Turkey. Cent Eur J Public Health. 2020;28(2):130–4. doi:10.21101/cejph.a5543.
   PubMed Web of Science ®Google Scholar
• Greenberg DP. Considerations for hepatitis B as part of a combination vaccine. Pediatr Infect Dis J. 2001;20(11 Suppl):S34–9. doi:10.1097/00006454-200111001-00006.
   PubMed Web of Science ®Google Scholar
• Stevens CE, Toy P, Kamili S, Taylor PE, Tong MJ, Xia G-L, Vyas GN. Eradicating hepatitis B virus: the critical role of preventing perinatal transmission. Biologicals. 2017;50:3–19. doi:10.1016/j.biologicals.2017.08.008.
   PubMed Web of Science ®Google Scholar
• Care. AGDoHaA. Australian government department of health and aged care; 2021. https://www.health.gov.au/resources/collections/nndss-public-datasets?utm_source=health.gov.au&utm_medium=callout-auto-custom&utm_campaign=digital_transformation.
   Google Scholar
• Mogale M, Burnett RJ, Olivier D, Mphahlele J. Economic assessment of implementing Hexaxim® vaccine within the South African expanded programme on immunisation (EPI-SA). Int J Infect Dis. 2014;21:430. doi:10.1016/j.ijid.2014.03.1307.
   Web of Science ®Google Scholar
• Aljunid SM, Al Bashir L, Ismail AB, Aizuddin AN, Rashid SAZA, Nur AM. Economic impact of switching from partially combined vaccine “Pentaxim® and hepatitis B” to fully combined vaccine “Hexaxim®” in the Malaysian national immunization program. BMC Health Serv Res. 2022;22(1):34. doi:10.1186/s12913-021-07428-7.
   PubMed Web of Science ®Google Scholar
• Fagnani F, Le Fur C, Durand I, Gibergy M. Economic evaluation of a combined DTPa, hepatitis B, polio, Hib vaccine. Eur J Health Econ Formerly. 2004;5(2):143–9. doi:10.1007/s10198-003-0216-z.
   PubMedGoogle Scholar
• Demarteau N, Geets R, Kapun AP. Budget impact associated with the implementation of a Dtpa-Ipv-Hepb/Hib hexa vaccination program in Slovenia. Value in Health. 2016;19(7):A410. doi:10.1016/j.jval.2016.09.367.
   Web of Science ®Google Scholar